University of Patras
Απεικονιστική διερεύνηση λεμφωμάτων με το ραδιοσημασμένο ανάλογο της σωματοστατίνης 99mTc depreotide
Abstract
dc:descriptionPrevious studies have demonstrated the feasibility of targeting lymphoma lesions with somatostatin receptor binding agents, mainly with In-111-pentetreotide. However, Pentreotide has not been established as a useful radiopharmaceutical for lymphoma diagnosis, mainly due to nonuniform uptake in lymphoma lesions leading to variable sensitivity. In the present study, the potential value of the Tc-99m-depreotide scintigraphy in a series of patients with various lymphoma types, prior to and post-therapy is investigated. Depreotide was directly compared to Ga-67. We used contemporary hybrid imaging technology with both radioisotopic agents, namely single photon emission tomography coupled with low resolution computerized tomography (SPECT/CT). Methods: One-hundred and six patients, 47 with Hodgkin’s (HL) and 59 with various types of non-Hodgkin’s lymphoma (NHL) were imaged with both Tc-99m-depreotide and Ga-67 citrate. Planar whole-body and SPECT/CT images were obtained. A total of 142 examinations were undertaken at different phases of the disease. Depreotide and gallium findings were compared visually and semi-quantitatively, with reference to the results of conventional work-up and the patients’ follow-up data. Results: In most HL, intermediate- and low-grade B-cell, as well as in T-cell NHL, depreotide depicted more lesions than Ga-67 and/or exhibited higher tumor uptake. The opposite was true in aggressive B-cell NHL. However, there were notable exceptions in all lymphoma subtypes. During initial staging, 93.3% of affected lymph nodes above the diaphragm, 100% of inguinal nodes and all cases with splenic infiltration were detected by depreotide. On the basis of depreotide findings 32% of patients with early stage HL were upstaged. However, advanced HL and NHL cases were frequently downstaged, due to low sensitivity for abdominal lymph node (22.7%), liver (45.5%) and bone marrow involvement (36.4%). Post-therapy, depreotide detected 94.7% of cases with refractory disease or recurrence. Its overall specificity was moderate (57.1%). Rebound thymic hyperplasia, various inflammatory processes and sites of unspecific uptake were the commonest causes of false positive findings. Combination of depreotide and gallium enhanced sensitivity (100%), while various false positive results of either agent could be avoided. Conclusion: Except perhaps for early-stage HL, Tc-99m-depreotide as a stand-alone imaging modality has a limited value for the initial staging of lymphomas. Post-therapy, however, depreotide scintigraphy seems useful in the evaluation of certain anatomic areas, particularly in non-aggressive lymphoma types. Combination with Ga-67 potentially enhances sensitivity and specificity. If flurodeoxyglucose positron emission tomography (PET) is not available or in case of certain indolent lymphoma types, Tc-99m depreotide may have a role as an adjunct to conventional imaging procedures.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papandrianos, Nikolaos
- Παπανδριανός, Νικόλαος
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27114